AvidBiotics split creates two biotechs in hot areas – BioPharma Dive
|
AvidBiotics split creates two biotechs in hot areas
BioPharma Dive Last month, following a patient death, the Food and Drug Administration put a clinical hold on two Phase 1 studies of Cellectis’ gene-edited allogeneic CAR–T therapy, UCART123, in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. |
FierceBiotech |
Chasing Biogen, AveXis posts improved gene therapy data
FierceBiotech AveXis has posted an update on the spinal muscular atrophy (SMA) patients treated with its gene therapy. The latest data show an uptick in the proportion of patients able to sit unassisted and talk, fueling AveXis’ hopes of establishing AVXS-101 as a … AveXis to Report Third Quarter 2017 Financial and Operating ResultsNasdaq |
European Biotechnology |
Another death related to allogenic CAR–T cell therapy
European Biotechnology Following the death of a patient with blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA put a hold on two clinical Phase I trails with UCART123, French Cellectis SA’s allogenic CAR–T therapies. Preliminary results from two trials in CD19+ … |
Scientific American |
Mail-Order CRISPR Kits Allow Absolutely Anyone to Hack DNA …
Scientific American Experts debate what amateur scientists could accomplish with the powerful DNA editing tool—and whether its ready availability is cause for concern. Study shows CRISPR can reverse mutations – The Johns Hopkins …Johns Hopkins News-Letter Potential Parkinson’s Treatment Seen in New Version of Gene …Parkinson’s News Today Syngenta obtains non-exclusive IP license from Broad Institute for …Digital Journal HDBuzz all 6 news articles » |
Scientific American |
Mail-Order CRISPR Kits Allow Absolutely Anyone to Hack DNA
Scientific American CRISPR–Cas9 (or CRISPR, for short) has given scientists a powerful way to make precise changes to DNA—in microbes, plants, mice, dogs and even in human cells. The technique may help researchers engineer drought-resistance crops, develop better … Study shows CRISPR can reverse mutationsJohns Hopkins News-Letter Potential Parkinson’s Treatment Seen in New Version of Gene …Parkinson’s News Today Syngenta obtains non-exclusive IP license from Broad Institute for …Digital Journal HDBuzz all 6 news articles » |
European Biotechnology |
Another death related to allogenic CAR–T cell therapy
European Biotechnology Following the death of a patient with blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA put a hold on two clinical Phase I trails with UCART123, French Cellectis SA’s allogenic CAR–T therapies. Preliminary results from two trials in CD19+ … |